In Ep. 138, we discussed the basics of vasopressor and inotrope use. During that podcast, I promised we would go more in-depth in subsequent episodes–this is one of those that will fulfill that promise. Angiotensin II is a new (old) player on the field. To discuss this topic and more on vasopressors, I asked Dr. Mink Chawla to join me on the podcast.
Conflict of Interest Disclaimer
Dr. Chawla is the CMO of La Jolla Pharmaceuticals, the manufacturer of Angiotensin II
Bio for Dr. Chawla
Dr. Chawla is Chief Medical Officer of La Jolla Pharmaceuticals. Dr. Chawla was an Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was also the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. Dr. Chawla was an active investigator in shock, inflammation and extracorporeal therapies, including: continuous renal replacement therapy, dialysis and albumin dialysis. Dr. Chawla is also the author of over 100 peer-reviewed publications and an Associate Editor for the Clinical Journal of the American Society of Nephrology.
Dr. Chawla's Maryland CC Project Lecture
Article Mentioned Regarding IntraOp Hypotension
- Walsh & Sessler et al.
- Also Check out: (Intens Care Med 2018;44:811)
Now on to the Podcast…
Angio II Papers
- The use of angiotensin II in distributive shock-
- Angiotensin II for the Treatment of Vasodilatory Shock – NEJM – 2017-(Athos 3)
- Angiotensin-II- More Than Just Another Vasoconstrictor to Treat Septic Shock–Induced Hypotension
- ATHOS-3 protocol & editorial, CCR_Mar_17_text
- Chawla-ATHOS-Crit Care-2014-(Athos 1)
Links of Interest
- Vasopressor Basics Show
- PulmCrit's Voodoo
- The Bottom Line on the Athos 3 Trial
- Why the FDA Approved AngioII